Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2018-04-30

2018

Birmpakou Antonia

Κωνσταντίνος Συρίγος, Καθηγητής, Ιατρική, ΕΚΠΑ
Παρασκευή Ρούσσου, Αναπληρώτρια Καθηγήτρια,Ιατρική, ΕΚΠΑ
Ανδριανή Χαρπίδου, Διδάκτωρ, Ιατρική, ΕΚΠΑ

Επίδραση χημειοθεραπείας στις γνωσιακές λειτουργίες των ασθενών με Ca πνεύμονα

English

Cognitive impairment in patients with lung cancer after chemotherapy treatment

The last decade global research supports the concept of chemobrain. The notion of the neurotoxic effects of chemotherapy on cognition (chemobrain), although initially described in the 1970s, only began to garner attention in the late 1990s as it became increasingly recognized as a common and significant symptom in cancer survivors. The phenomenon first came to light, because of the large number of breast cancer survivors, who presented with cognitive impairment. The foggy thinking, the lack of concentration and the short- term memory loss were present after treatment even for years. Little is known about who is most likely to suffer and how to fight against it. Unfortunately, due to low survival rate and the limited life expectancy of lung cancer patients, there is currently a small number of studies about chemobrain focused on these patients and a significant part of our knowledge derives from the use of the same chemotherapy agents on other neoplasms, mostly breast cancer.
The aim of the present study is to test whether treatment with chemotherapy in patients with lung cancer results in cognitive impairment. Patients with a confirmed diagnosis of lung cancer were included in the study. On the first day of admission for chemotherapy, all patients underwent physical examination and provided a complete medical history. The type of lung cancer, the detailed TNM stage, smoking status, performance status on admission and the therapeutic regiment were also recorded. The mini- mental state examination test was performed in all patients just before the initiation of the first treatment. We did not include patients with inability or unwillingness to cooperate with the investigators, patients with brain metastasis, patients with mental disorders, an already known diagnosis of dementia, and those who had received chemotherapy in the past for any kind of cancer. All patients were reevaluated 3 months later.
Our observations show that there was no effect of chemotherapy on lung cancer patients three months after the initiation of chemotherapy.

Health Sciences

Chemobrain, Cognitive impairment, Chemotherapy, Lung cancer

No

0

Yes

73

78

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2750695